Allogeneic Hematopoietic Cell Transplants for Sickle Cell Anemia and β -Thalassemia
Customize your policy alerts
Sign up for Arizona Complete Health Policy CP.MP.108 alerts
Get alerted when Policy CP.MP.108 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity criteria for non‑Medicare health plans affiliated with Centene for allogeneic hematopoietic cell transplants to treat sickle cell anemia and homozygous β-thalassemia and summarizes indications, contraindications, and unsupported scenarios.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Insufficient evidence / not supported
Not covered / insufficient evidence:
Autologous hematopoietic cell transplant (AHCT) for sickle cell anemia or β-thalassemia when not performed as part of a gene therapy protocol is considered to have insufficient evidence supporting its safety and efficacy and is therefore not supported by this policy.
Allogeneic hematopoietic cell transplant (HCT) for sickle cell anemia or homozygous β-thalassemia for any indications other than those explicitly specified in this policy is considered to have insufficient evidence and is not supported.
When state Medicaid coverage provisions conflict with this clinical policy, state Medicaid provisions take precedence. Providers should consult the applicable state Medicaid manual for specific coverage requirements before applying this policy.
Candidate Selection
Candidate selection
Candidate selection requirements for non-Medicare plans:
Contraindications
Absolute contraindications that must be absent for coverage include: infections with highly virulent and/or resistant microbes that are poorly controlled pretransplant and an inability to adhere to the regimen necessary to preserve the transplant, even with caregiver support.
Active substance use or dependence is an absolute contraindication unless there is convincing evidence of sustained risk-reduction behaviors. This includes current tobacco use, vaping, marijuana use (unless prescribed by a licensed practitioner), or IV drug use. An exception may be considered if urgent transplant timelines exist and the patient commits to risk-reduction behaviors.
Pre-Transplant Evaluation Requirements
Document donor HLA match and stem cell source
Documentation of donor HLA-matching and specification of the stem cell source (cord blood, bone marrow, or peripheral blood when donor unable/refuses bone marrow) must be provided as part of the evaluation.
- For homozygous β-thalassemia the donor must be HLA-matched and the stem cell source must be specified: cord blood, bone marrow, or peripheral blood only if donor unable/refuses bone marrow.
- For sickle cell anemia an HLA-matched, first‑degree relative donor must be documented.
Provider Actions, Authorization, and Documentation
Obtain prior authorization and include referenced codes
Prior authorization is required for allogeneic hematopoietic cell transplant procedures; submit requests referencing the informational procedure codes listed in the policy.
Check Medicare and state Medicaid rules before authorization
Verify applicable Medicare NCDs/LCDs and state Medicaid coverage rules before applying this clinical policy or finalizing prior authorization decisions.
- For Medicaid members, state Medicaid provisions take precedence—refer to the state Medicaid manual.
- For Medicare members, review all applicable NCDs, LCDs, and Medicare Coverage Articles on the CMS website prior to applying these criteria.
No step therapy required — coverage based on meeting criteria
No step therapy sequencing is prescribed by this policy; coverage is contingent on meeting the transplant indications and absence of absolute contraindications listed.
- Ensure patient meets one of the specified disease indications and planned conditioning regimen is standard myeloablative.
- Confirm absence of absolute contraindications (e.g., uncontrolled virulent/resistant infection, inability to adhere, active substance use without risk reduction).
Include required clinical documentation to support indication and regimen
Clinical documentation submitted for authorization must support the specific indication and treatment plan, including HLA match/donor source, history of stroke or high stroke risk or recurrent complications for sickle cell, transfusion dependence for β-thalassemia, and the planned conditioning regimen.
- Document evidence of prior stroke, recurrent acute chest syndrome, recurrent vaso-occlusive crises, or RBC alloimmunization when indicating stroke/high risk in sickle cell anemia.
- Document transfusion dependence when indicating transplant for β-thalassemia.
- Document planned use of a standard myeloablative conditioning regimen.
Provider responsibility for documentation and medical judgment
This clinical policy is guidance for medical necessity determinations; providers are expected to exercise professional judgment and ensure submitted documentation aligns with standards of medical practice and applicable requirements.
- Providers remain responsible for medical judgment and treatment decisions and must ensure documentation aligns with state/federal requirements.
- The policy does not dictate care and should not replace clinical decision‑making.
Incomplete documentation or unmet indications may lead to denial
Requests that do not document that all required indications and absence of absolute contraindications are met risk denial for lack of medical necessity.
- Examples of denial triggers include missing documentation of an HLA‑matched donor when required, lack of evidence for stroke/high stroke risk in sickle cell, or presence of uncontrolled infection or active substance use without evidence of risk reduction.
Provider notice regarding policy purpose and plan processes
This clinical policy was developed by experienced professionals to guide medical necessity determinations; providers should note the policy’s purpose and that it does not guarantee payment—follow plan-specific submission and notification requirements.
- The policy is a guide to medical necessity and is subject to plan terms, state/federal law, and Health Plan administrative policies.
- Providers should follow applicable plan notification and submission processes.
Medicaid precedence — follow state Medicaid provisions
When state Medicaid coverage provisions conflict with this clinical policy, state Medicaid provisions take precedence; providers should follow state Medicaid manual requirements for Medicaid members.
- Failure to follow applicable state Medicaid or Medicare NCD/LCD requirements may affect coverage determinations.
Informational Procedure and Billing Codes
| S2150 | Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre- and posttransplant care in the global definition. |
Comprehensive Transplant-Related Services
Transplant Center Requirements
No center accreditation or volume requirements specified
The policy excerpt does not specify FACT accreditation, center volume, or other formal transplant center requirements in this section.
- No explicit accreditation or minimum-volume requirements are stated for centers in this policy portion.
Definitions
Background and Clinical Context
Sickle cell anemia and homozygous β-thalassemia are monogenic hemoglobinopathies that cause chronic hemolytic anemia and multi-organ complications. Sickle cell disease results from a β-globin mutation leading to sickling of red blood cells with vaso-occlusion, pain crises, and risk of stroke; β-thalassemia major results from mutations that reduce β-globin synthesis, causing ineffective erythropoiesis, severe anemia, and transfusion dependence.
Allogeneic hematopoietic cell transplant is described in the literature as the only curative therapy for these conditions in selected patients, with reported high success rates in specific pediatric cohorts and variable long-term survival in thalassemia series. Clinical selection depends on disease-specific indications, availability of an appropriate HLA-matched donor, stem cell source, and planned use of a standard myeloablative conditioning regimen.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.